Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP3 | P08254 | 17/20 | 0.81 |
| ▸ | MMP9 | P14780 | 15/20 | 0.81 |
| ▸ | MMP1 | P03956 | 14/20 | 0.81 |
| ▸ | ADAM17 | P78536 | 11/20 | 0.81 |
| ▸ | MMP2 | P08253 | 4/20 | 0.52 |
| ▸ | MMP7 | P09237 | 2/20 | 0.51 |
| ▸ | MMP12 | P39900 | 1/20 | 0.50 |
| ▸ | MMP13 | P45452 | 3/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5342363 | 1.00 | MMP3 (0.81) | MMP3MMP9MMP1ADAM17MMP2 | |
| SCHEMBL5338174 | 1.00 | MMP3 (0.81) | MMP3MMP9MMP1ADAM17MMP2 | |
| SCHEMBL5352447 | 0.90 | MMP3 (0.67) | MMP3MMP9MMP1ADAM17MMP2 | |
| SCHEMBL5351412 | 0.90 | MMP3 (0.67) | MMP3MMP9MMP1ADAM17MMP2 | |
| SCHEMBL5337192 | 0.90 | MMP3 (1.00) | MMP3MMP9MMP1ADAM17MMP2 | |
| SCHEMBL14532367 | 0.87 | MMP3 (0.69) | MMP3MMP9MMP1ADAM17MMP7 | |
| SCHEMBL5343121 | 0.86 | MMP3 (0.81) | MMP3MMP9MMP1ADAM17MMP2 | |
| SCHEMBL5351800 | 0.86 | MMP3 (0.61) | MMP3MMP9MMP1ADAM17MMP2 | |
| SCHEMBL5922442 | 0.86 | ADAM17 (0.61) | MMP3MMP9MMP1ADAM17MMP2 | |
| SCHEMBL5345757 | 0.86 | MMP3 (0.67) | MMP3MMP9MMP1ADAM17MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7223779-B2 | Azasugar derivative and drug containing the same as the active ingredient | CARNA BIOSCIENCES INC. (JP) | 2007-05-29 | — | — | US | disclosed |
| US-7223779-B2 | Azasugar derivative and drug containing the same as the active ingredient | CARNA BIOSCIENCES INC. (JP) | 2007-05-29 | — | — | US | disclosed |
| US-7223779-B2 | Azasugar derivative and drug containing the same as the active ingredient | CARNA BIOSCIENCES INC. (JP) | 2007-05-29 | — | — | US | disclosed |
| US-20050154017-A1 | Novel azasugar derivative and drug containing the same as the active ingredient | CARNA BIOSCIENCES INC. (JP) | 2005-07-14 | — | — | US | disclosed |
| US-20050137221-A1 | Novel azasugar derivative and drug containing the same as the active ingredient | TSUKIDA TAKAHIRO (JP) | 2005-06-23 | — | — | US | disclosed |
| EP-1516872-A1 | NOVEL AZASUGAR DERIVATIVE AND DRUG CONTAINING THE SAME AS THE ACTIVE INGREDIENT | Carna Biosciences Inc. (JP) | 2005-03-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050154017-A1 | Novel azasugar derivative and drug containing the same as the active ingredient | CDK8, DUT, CDK7 | MMP3 2136/4885MMP9 1503/4885MMP1 815/4885 |
| US-20050137221-A1 | Novel azasugar derivative and drug containing the same as the active ingredient | CDK8, DUT, CDK7 | MMP3 2136/4885MMP9 1503/4885MMP1 815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.